Hims & Hers is growing internationally and strengthening its healthcare platform beyond longevity therapies, supported by a $400 million JPMorgan receivables facility that enhances financial flexibility for GLP-1 expansion without dilutive equity financing. The recent $1.15 billion acquisition of Eucalyptus adds 850,000 customers and about $450 million in annual recurring revenue across eight international markets. Despite FDA staff challenges on compounded peptides, Hims & Hers trades at a low forward valuation with expected strong revenue growth in 2026 and 2027. Risks include regulatory uncertainty, convertible note dilution, integration of Eucalyptus, and high market expectations.
